<unk>  is rapidly absorbed (Cmax attained 2–3 hours after single 2 mg oral dose) and is extensively distributed. Metabolism is not the major route of elimination. In vitro, human liver metabolism is very slow and only minor amounts of metabolites are found. A large fraction of the active substance is excreted unchanged (about 60% of the administered dose in urine and at least 6% in feces). Renal excretion of unchanged<unk>  involves both passive filtration and active secretion. Plasma clearance averages 317 ml/min, terminal half-life is 24–30 hours, and steady-state is reached within 3–4 days. On once daily treatment with 2 mg<unk> , steady-state plasma concentrations fluctuate between trough and peak values of 2.5 and 7 ng/ml, respectively. In vitro data indicate that<unk>  has a low interaction potential, and therapeutic concentrations of<unk>  are not expected to affect the CYP-mediated metabolism of co-medicated medicinal products.
Prucalopride
Bromopride
Itopride
Cinitapride
Tasimelteon
Lorcaserin
Sibutramine
Palonosetron